Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022
Trevi Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on November 10, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and provide a corporate update. The focus will be on its investigational therapy, Haduvio, for chronic cough conditions. The company has completed a Phase 2 trial for Haduvio's efficacy in treating chronic cough linked to idiopathic pulmonary fibrosis (IPF) and aims to target further development in chronic cough conditions including IPF and refractory chronic cough.
- Successfully completed a Phase 2 trial for Haduvio targeting chronic cough in IPF.
- Plans to focus on chronic cough conditions, which could expand market potential.
- None.
Conference call and webcast to be held at 4:30 p.m. EDT
NEW HAVEN, Conn., Nov. 3, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of serious chronic cough conditions, today announced that management will host a conference call and live audio webcast on Thursday, November 10, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2022.
To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 4950734. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of serious chronic cough conditions. The Company has successfully completed a Phase 2 trial of Haduvio for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF). Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).
For more information, visit www.TreviTherapeutics.com and follow the company on Twitter and LinkedIn.
About Haduvio
Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are centrally and peripherally active and known to be critical mediators of cough and itch. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Parenteral nalbuphine is not currently scheduled as a controlled substance by the DEA in the United States or by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q3-2022-financial-results-and-provide-a-corporate-update-on-november-10-2022-301668183.html
SOURCE Trevi Therapeutics, Inc.
FAQ
When will Trevi Therapeutics report its Q3 2022 financial results?
What investigational therapy is Trevi Therapeutics developing?
What was the outcome of Trevi's Phase 2 trial for Haduvio?
How can I participate in Trevi Therapeutics' conference call?
